{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:37:10Z","timestamp":1786981030603,"version":"build-2736575974"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T00:00:00Z","timestamp":1538611200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["NSC.104-2314-B-075-023-MY2"],"award-info":[{"award-number":["NSC.104-2314-B-075-023-MY2"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"crossref","award":["V103C-012"],"award-info":[{"award-number":["V103C-012"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s10620-018-5311-1","type":"journal-article","created":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T10:07:08Z","timestamp":1538647628000},"page":"102-112","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Dabigatran Reduces Liver Fibrosis in Thioacetamide-Injured Rats"],"prefix":"10.1007","volume":"64","author":[{"given":"Kuei-Chuan","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Fan","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Cheng","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Che-Chang","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Ying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hsiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Chih","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Chieh","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,4]]},"reference":[{"key":"5311_CR1","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1016\/S0168-8278(02)00429-4","volume":"38","author":"SL Friedman","year":"2003","unstructured":"Friedman SL. Liver fibrosis\u2014from bench to bedside. J Hepatol. 2003;38:S38\u2013S53.","journal-title":"J Hepatol."},{"key":"5311_CR2","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1053\/j.gastro.2008.03.003","volume":"134","author":"SL Friedman","year":"2008","unstructured":"Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008;134:1655\u20131669.","journal-title":"Gastroenterology."},{"key":"5311_CR3","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1053\/gast.1996.v110.pm8566602","volume":"110","author":"M Pinzani","year":"1996","unstructured":"Pinzani M, Milani S, De Franco R, et al. Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells. Gastroenterology. 1996;110:534\u2013548.","journal-title":"Gastroenterology."},{"key":"5311_CR4","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1002\/hep.23123","volume":"50","author":"Y Popov","year":"2009","unstructured":"Popov Y, Schuppan D. Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies. Hepatology. 2009;50:1294\u20131306.","journal-title":"Hepatology."},{"key":"5311_CR5","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/35025229","volume":"407","author":"SR Coughlin","year":"2000","unstructured":"Coughlin SR. Thrombin signalling and protease-activated receptors. Nature. 2000;407:258\u2013264.","journal-title":"Nature."},{"key":"5311_CR6","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.2353\/ajpath.2010.100425","volume":"177","author":"BP Sullivan","year":"2010","unstructured":"Sullivan BP, Weinreb PH, Violette SM, Luyendyk JP. The coagulation system contributes to alphaVbeta6 integrin expression and liver fibrosis induced by cholestasis. Am J Pathol. 2010;177:2837\u20132849.","journal-title":"Am J Pathol"},{"key":"5311_CR7","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/hep.20054","volume":"39","author":"S Fiorucci","year":"2004","unstructured":"Fiorucci S, Antonelli E, Distrutti E, et al. PAR1 antagonism protects against experimental liver fibrosis. Role of proteinase receptors in stellate cell activation. Hepatology. 2004;39:365\u2013375.","journal-title":"Hepatology."},{"key":"5311_CR8","first-page":"20","volume":"43","author":"JM Rhea","year":"2011","unstructured":"Rhea JM, Molinaro RJ. Direct thrombin inhibitors: clinical uses, mechanism of action, and laboratory measurement. MLO Med Lab Obs. 2011;43:20\u201322.","journal-title":"MLO Med Lab Obs."},{"key":"5311_CR9","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1124\/jpet.114.218545","volume":"351","author":"AK Kopec","year":"2014","unstructured":"Kopec AK, Joshi N, Towery KL, et al. Thrombin inhibition with dabigatran protects against high-fat diet-induced fatty liver disease in mice. J Pharmacol Exp Ther. 2014;351:288\u2013297.","journal-title":"J Pharmacol Exp Ther."},{"key":"5311_CR10","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.ajpath.2012.06.011","volume":"181","author":"KM Kassel","year":"2012","unstructured":"Kassel KM, Sullivan BP, Cui W, Copple BL, Luyendyk JP. Therapeutic administration of the direct thrombin inhibitor argatroban reduces hepatic inflammation in mice with established fatty liver disease. Am J Pathol. 2012;181:1287\u20131295.","journal-title":"Am J Pathol."},{"key":"5311_CR11","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1161\/ATVBAHA.110.203604","volume":"30","author":"WG Eisert","year":"2010","unstructured":"Eisert WG, Hauel N, Stangier J, Wienen W, Clemens A, van Ryn J. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Vasc Biol. 2010;30:1885\u20131889.","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"5311_CR12","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1097\/ALN.0000000000000255","volume":"120","author":"J Ryn van","year":"2014","unstructured":"van Ryn J, Schurer J, Kink-Eiband M, Clemens A. Reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat-tail bleeding model and lack of effect on assays of coagulation. Anesthesiology. 2014;120:1429\u20131440.","journal-title":"Anesthesiology."},{"key":"5311_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1042\/CS20090601","volume":"119","author":"KC Lee","year":"1979","unstructured":"Lee KC, Yang YY, Huang YT, et al. Administration of a low dose of sildenafil for 1\u00a0week decreases intrahepatic resistance in rats with biliary cirrhosis: the role of NO bioavailability. Clin Sci. 1979;119:45\u201355.","journal-title":"Clin Sci."},{"key":"5311_CR14","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.jhep.2015.12.003","volume":"64","author":"F Cerini","year":"2016","unstructured":"Cerini F, Vilaseca M, Lafoz E, et al. Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats. J Hepatol. 2016;64:834\u2013842.","journal-title":"J Hepatol."},{"key":"5311_CR15","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.2353\/ajpath.2008.080512","volume":"173","author":"JS Blackburn","year":"2008","unstructured":"Blackburn JS, Brinckerhoff CE. Matrix metalloproteinase-1 and thrombin differentially activate gene expression in endothelial cells via PAR-1 and promote angiogenesis. Am J Pathol. 2008;173:1736\u20131746.","journal-title":"Am J Pathol."},{"key":"5311_CR16","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.jhep.2008.12.011","volume":"50","author":"M Fernandez","year":"2009","unstructured":"Fernandez M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J. Angiogenesis in liver disease. J Hepatol. 2009;50:604\u2013620.","journal-title":"J Hepatol."},{"key":"5311_CR17","doi-asserted-by":"publisher","first-page":"e69309","DOI":"10.1371\/journal.pone.0069309","volume":"8","author":"JH Gao","year":"2013","unstructured":"Gao JH, Wen SL, Yang WJ, et al. Celecoxib ameliorates portal hypertension of the cirrhotic rats through the dual inhibitory effects on the intrahepatic fibrosis and angiogenesis. PloS One. 2013;8:e69309.","journal-title":"PloS One."},{"key":"5311_CR18","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s10456-016-9522-9","volume":"19","author":"JH Gao","year":"2016","unstructured":"Gao JH, Wen SL, Feng S, et al. Celecoxib and octreotide synergistically ameliorate portal hypertension via inhibition of angiogenesis in cirrhotic rats. Angiogenesis. 2016;19:501\u2013511.","journal-title":"Angiogenesis."},{"key":"5311_CR19","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1053\/j.gastro.2008.12.001","volume":"136","author":"J Zhang","year":"2009","unstructured":"Zhang J, Luo B, Tang L, et al. Pulmonary angiogenesis in a rat model of hepatopulmonary syndrome. Gastroenterology. 2009;136:1070\u20131080.","journal-title":"Gastroenterology."},{"key":"5311_CR20","first-page":"1238","volume":"21","author":"IR Wanless","year":"1995","unstructured":"Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology. 1995;21:1238\u20131247.","journal-title":"Hepatology."},{"key":"5311_CR21","first-page":"550","volume":"43","author":"F Violi","year":"1995","unstructured":"Violi F, Ferro D, Basili S, et al. Increased rate of thrombin generation in hepatitis C virus cirrhotic patients. Relationship to venous thrombosis. J Investig Med. 1995;43:550\u2013554.","journal-title":"J Investig Med."},{"key":"5311_CR22","first-page":"780","volume":"22","author":"F Marra","year":"1995","unstructured":"Marra F, Grandaliano G, Valente AJ, Abboud HE. Thrombin stimulates proliferation of liver fat-storing cells and expression of monocyte chemotactic protein-1: potential role in liver injury. Hepatology. 1995;22:780\u2013787.","journal-title":"Hepatology"},{"key":"5311_CR23","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/hep.24784","volume":"55","author":"V Knight","year":"2012","unstructured":"Knight V, Tchongue J, Lourensz D, Tipping P, Sievert W. Protease-activated receptor 2 promotes experimental liver fibrosis in mice and activates human hepatic stellate cells. Hepatology. 2012;55:879\u2013887.","journal-title":"Hepatology."},{"key":"5311_CR24","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s12072-012-9391-2","volume":"7","author":"M Kukla","year":"2013","unstructured":"Kukla M. Angiogenesis: a phenomenon which aggravates chronic liver disease progression. Hepatol Int. 2013;7:4\u201312.","journal-title":"Hepatol Int."},{"key":"5311_CR25","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.2353\/ajpath.2007.060887","volume":"170","author":"E Novo","year":"2007","unstructured":"Novo E, Cannito S, Zamara E, et al. Proangiogenic cytokines as hypoxia-dependent factors stimulating migration of human hepatic stellate cells. Am J Pathol. 2007;170:1942\u20131953.","journal-title":"Am J Pathol."},{"key":"5311_CR26","doi-asserted-by":"publisher","first-page":"3847","DOI":"10.4049\/jimmunol.1303195","volume":"192","author":"A Mochizuki","year":"2014","unstructured":"Mochizuki A, Pace A, Rockwell CE, et al. Hepatic stellate cells orchestrate clearance of necrotic cells in a hypoxia-inducible factor-1alpha-dependent manner by modulating macrophage phenotype in mice. J Immunol. 2014;192:3847\u20133857.","journal-title":"J Immunol."},{"key":"5311_CR27","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s11010-011-1016-x","volume":"359","author":"Y Zhao","year":"2012","unstructured":"Zhao Y, Wang Y, Wang Q, Liu Z, Liu Q, Deng X. Hepatic stellate cells produce vascular endothelial growth factor via phospho-p44\/42 mitogen-activated protein kinase\/cyclooxygenase-2 pathway. Mol Cell Biochem. 2012;359:217\u2013223.","journal-title":"Mol Cell Biochem."},{"key":"5311_CR28","doi-asserted-by":"publisher","first-page":"e74051","DOI":"10.1371\/journal.pone.0074051","volume":"8","author":"Y Wang","year":"2013","unstructured":"Wang Y, Huang Y, Guan F, et al. Hypoxia-inducible factor-1alpha and MAPK co-regulate activation of hepatic stellate cells upon hypoxia stimulation. PloS One. 2013;8:e74051.","journal-title":"PloS One."},{"key":"5311_CR29","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1056\/NEJMra1011170","volume":"365","author":"A Tripodi","year":"2011","unstructured":"Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med. 2011;365:147\u2013156.","journal-title":"N Engl J Med."},{"key":"5311_CR30","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/ajg.2008.34","volume":"104","author":"KK Sogaard","year":"2009","unstructured":"Sogaard KK, Horvath-Puho E, Gronbaek H, Jepsen P, Vilstrup H, Sorensen HT. Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study. Am J Gastroenterol. 2009;104:96\u2013101.","journal-title":"Am J Gastroenterol."},{"key":"5311_CR31","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jhep.2014.03.013","volume":"61","author":"A Tripodi","year":"2014","unstructured":"Tripodi A, Fracanzani AL, Primignani M, et al. Procoagulant imbalance in patients with nonalcoholic fatty liver disease. J Hepatol. 2014;61:148\u2013154.","journal-title":"J Hepatol."},{"key":"5311_CR32","doi-asserted-by":"publisher","first-page":"e1251","DOI":"10.1053\/j.gastro.2012.07.018","volume":"143","author":"E Villa","year":"2012","unstructured":"Villa E, Camma C, Marietta M, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology. 2012;143:e1251\u2013e1254.","journal-title":"Gastroenterology."},{"key":"5311_CR33","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1002\/hep.29084","volume":"65","author":"M Vilaseca","year":"2017","unstructured":"Vilaseca M, Garcia-Caldero H, Lafoz E, et al. The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells. Hepatology. 2017;65:2031\u20132044.","journal-title":"Hepatology."},{"key":"5311_CR34","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1111\/liv.13285","volume":"37","author":"A Gottardi De","year":"2017","unstructured":"De Gottardi A, Trebicka J, Klinger C, et al. Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. Liver Int. 2017;37:694\u2013699.","journal-title":"Liver Int."},{"key":"5311_CR35","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s40262-013-0034-0","volume":"52","author":"J Graff","year":"2013","unstructured":"Graff J, Harder S. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment. Clin Pharmacokinet. 2013;52:243\u2013254.","journal-title":"Clin Pharmacokinet."},{"key":"5311_CR36","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1124\/dmd.110.033696","volume":"38","author":"T Ebner","year":"2010","unstructured":"Ebner T, Wagner K, Wienen W. Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. Drug Metab Dispos. 2010;38:1567\u20131575.","journal-title":"Drug Metab Dispos."},{"key":"5311_CR37","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.jhep.2014.05.047","volume":"61","author":"Y Iwakiri","year":"2014","unstructured":"Iwakiri Y, Shah V, Rockey DC. Vascular pathobiology in chronic liver disease and cirrhosis: current status and future directions. J Hepatol. 2014;61:912\u2013924.","journal-title":"J Hepatol."},{"key":"5311_CR38","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1016\/j.jhep.2008.01.021","volume":"48","author":"J Bosch","year":"2008","unstructured":"Bosch J, Berzigotti A, Garcia-Pagan JC, Abraldes JG. The management of portal hypertension: rational basis, available treatments and future options. J Hepatol. 2008;48:S68\u2013S92.","journal-title":"J Hepatol."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-018-5311-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-5311-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-5311-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T19:24:33Z","timestamp":1570130673000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-018-5311-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,4]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["5311"],"URL":"https:\/\/doi.org\/10.1007\/s10620-018-5311-1","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,4]]},"assertion":[{"value":"28 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}